SCHEMBL20076067

SCHEMBL20076067

COC(=O)c1cc(Br)cc(F)c1C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.42
SOS1 Q07889 1/20 0.41
NR4A2 P43354 1/20 0.40
GAA P10253 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 2/20 0.39
TSHR P16473 2/20 0.38
HTT P42858 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA7 P43166 3/20 0.37
CA9 Q16790 3/20 0.37
CA14 Q9ULX7 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
DGAT1 O75907 1/20 0.37
PDK2 Q15119 1/20 0.37
PDK4 Q16654 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252864 0.90 TSHR (0.46) NOTUMSOS1NR4A2GAAALDH1A1
SCHEMBL23526095 0.90 NOTUM (0.41) NOTUMSOS1NR4A2GAAALDH1A1
SCHEMBL517686 0.89 NOTUM (0.47) NOTUMSOS1GAAALDH1A1TSHR
SCHEMBL25839669 0.88 KMT2A (0.48) NOTUMHSD17B10TSHRHTTCA12
SCHEMBL30498167 0.84 SOS1 (0.45) NOTUMSOS1NR4A2GAAALDH1A1
SCHEMBL25751456 0.84 SOS1 (0.45) NOTUMSOS1NR4A2GAAALDH1A1
SCHEMBL1041318 0.82 CYP3A4 (0.47) NOTUMGAAALDH1A1TSHRHTT
SCHEMBL29429473 0.82 CYP3A4 (0.47) NOTUMGAAALDH1A1TSHRHTT
SCHEMBL17419113 0.82 CYP3A4 (0.47) NOTUMGAAALDH1A1TSHRHTT
SCHEMBL21198962 0.82 NOTUM (0.42) NOTUMSOS1NR4A2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4509184-A2 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2025-02-19 EP disclosed
US-20250034096-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2025-01-30 US disclosed
EP-3526202-B1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2025-01-08 EP disclosed
US-12077509-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-09-03 US disclosed
US-11964945-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-04-23 US disclosed
US-11952347-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-04-09 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
EP-3660004-B1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2023-02-22 EP disclosed
US-20210040044-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-02-11 US disclosed
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-01-14 US disclosed
US-10844021-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2020-11-24 US disclosed
CN-111892577-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2020-11-06 CN disclosed
EP-3660004-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2020-06-03 EP disclosed
EP-3660004-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2020-06-03 EP disclosed
US-20200095205-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2020-03-26 US disclosed
US-10584101-B2 Compounds and methods for the targeted degradation of androgen receptor Arvinas, Inc. (US) 2020-03-10 US disclosed
WO-2018071606-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. (US) 2018-04-19 WO disclosed
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN NOTUM 1806/4885SOS1 2078/4885NR4A2 429/4885
US-20210040044-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN NOTUM 1820/4885SOS1 2087/4885NR4A2 438/4885
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN NOTUM 1806/4885SOS1 2078/4885NR4A2 429/4885
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN NOTUM 1820/4885SOS1 2087/4885NR4A2 438/4885
US-10844021-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN NOTUM 1820/4885SOS1 2087/4885NR4A2 438/4885
US-11964945-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN NOTUM 1820/4885SOS1 2087/4885NR4A2 438/4885
US-11952347-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN NOTUM 1806/4885SOS1 2078/4885NR4A2 429/4885
US-12077509-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN NOTUM 1806/4885SOS1 2078/4885NR4A2 429/4885
US-20250034096-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN NOTUM 1806/4885SOS1 2078/4885NR4A2 429/4885
US-20200095205-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN NOTUM 1820/4885SOS1 2087/4885NR4A2 438/4885
US-10584101-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN NOTUM 1820/4885SOS1 2087/4885NR4A2 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.